FindTrial
Sign In

Ustekinumab (UST)

DRUG5 trials

Sponsors

Alimentiv Inc., Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital

Conditions

CD - Crohn's DiseaseCrohn Disease (CD)Crohn's DiseaseIBD - Inflammatory Bowel DiseaseInflamatory Bowel DiseaseInflammatory Bowel Disease (IBD)Stricture; Bowel

Unknown Phase

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Active, not recruitingNCT06249555
Alimentiv Inc.Crohn's Disease
Start: 2024-03-20End: 2026-12-01Target: 300Updated: 2026-08-21
An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
CompletedNCT07057856
Second Affiliated Hospital of Wenzhou Medical UniversityCrohn's Disease
Start: 2018-01-01End: 2025-05-31Updated: 2025-07-10
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
RecruitingNCT07444060
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCD - Crohn's Disease, IBD - Inflammatory Bowel Disease, Stricture; Bowel
Start: 2026-03-01End: 2029-12-31Target: 100Updated: 2026-03-02
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
RecruitingNCT07694674
Shanghai 10th People's HospitalCrohn Disease (CD), Inflamatory Bowel Disease
Start: 2026-01-16End: 2026-10-31Target: 198Updated: 2026-07-10
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
CompletedNCT07697547
Shanghai 10th People's HospitalCrohn's Disease, Inflammatory Bowel Disease (IBD)
Start: 2023-07-01End: 2026-03-31Updated: 2026-07-13